>
Tenzing Acquisition logo

TZACU - Tenzing Acquisition Share Price

$11.5 -12.2  -51.5%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6849
Bullish
Bearish
Unlock TZACU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 August 2020, RevivaPharmaceuticals Holdings, Inc. revenues was not reported.Net loss totaled $672K vs. income of $613K. Net lossreflects Interest income decrease of 84% to $119K (income),Operating costs increase of 60% to $265K (expense), G/L onInvest HFS, Maturity & Trading decrease from $28K (income)to $0K. Basic Earnings per Share excluding ExtraordinaryItems decreased from $0.24 to -$0.25.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TZACU Revenue Unlock TZACU Revenue

Net Income

TZACU Net Income Unlock TZACU Revenue

Normalised EPS

TZACU Normalised EPS Unlock TZACU Revenue

PE Ratio Range

TZACU PE Ratio Range Unlock TZACU Revenue

Dividend Yield Range

TZACU Dividend Yield Range Unlock TZACU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
TZACU EPS Forecasts Unlock TZACU Revenue
Profile Summary

Reviva Pharmaceuticals Holdings, Inc., formerly Tenzing Acquisition Corp., is a holding company. The Company, through its subsidiary Reviva Pharmaceuticals, Inc, is principally engaged in developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. The Company's pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms. It also intends to develop RP5063 for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound in clinical development. The Company's RP1208 is a novel triple reuptake inhibitor, which is engaged in enabling studies for depression and animal efficacy studies for obesity.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Capital Market
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
TZACU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to TZACU
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.